Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claes R Andersson

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
SLAS Technology|December 5, 2024
Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo modelsTove Selvin, Malin Berglund, Anders Åkerström, et al.
BMC Pharmacology & Toxicology|March 5, 2024
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessmentTove Selvin, Malin Berglund, Lena Lenhammar, et al.
Scientific Reports|August 6, 2020
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathwayClaes R Andersson, Tove Selvin, Kristin Blom, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
SLAS Technology|December 5, 2024
Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo modelsTove Selvin, Malin Berglund, Anders Åkerström, et al.
BMC Pharmacology & Toxicology|March 5, 2024
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessmentTove Selvin, Malin Berglund, Lena Lenhammar, et al.
Scientific Reports|August 6, 2020
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathwayClaes R Andersson, Tove Selvin, Kristin Blom, et al.
Pageof 2